The Netherlands
Requests for the withdrawal of marketing authorizations and parallel import licenses for human medicines effective 31 December 2025 — the so-called “end-of-year withdrawals” — must be received by the Medicines Evaluation Board (CBG) no later than 1 November 2025. Requests submitted by this date will be processed in time to avoid the annual fee for 2026.
Requests received on or after 2 November 2025 will only be processed after 1 January 2026, meaning the authorization will remain active at year-end, and the annual fee for 2026 will apply.
Withdrawals involving combined package leaflets must be submitted per medicinal product group in a separate CESP submission. Submissions containing multiple product groups in a single CESP file cannot be accepted. Withdrawals without leaflet changes may still be submitted together in one CESP submission.